Sangamo Therapeutics (SGMOQ) Amortization of Deferred Charges (2022 - 2025)

Sangamo Therapeutics' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $924000.0 for Q4 2025.

• On a quarterly basis, Amortization of Deferred Charges rose 3.36% year-over-year to $924000.0 in Q4 2025; TTM through Dec 2025 was $3.6 million, a 14.41% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 14.41% from the prior year.
• Amortization of Deferred Charges grew to $924000.0 in Q4 2025 per SGMOQ's latest filing, from $909000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $2.1 million in Q4 2022 and bottomed at $894000.0 in Q4 2024.
• The 4-year median for Amortization of Deferred Charges is $1.1 million (2024), against an average of $1.3 million.
• Across the five-year window, Amortization of Deferred Charges slumped 52.83% in 2024 and grew 3.36% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $2.1 million in 2022, then sank by 43.63% to $1.2 million in 2023, then declined by 24.37% to $894000.0 in 2024, then rose by 3.36% to $924000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Amortization of Deferred Charges figures stand at $924000.0 (Q4 2025), $909000.0 (Q3 2025), and $904000.0 (Q2 2025).